Pulmo BioTech Inc. (PLMO.OB) Completes DFH-12 Studies
Pulmo BioTech Incorporated announced this week that its subsidiary, PulmoScience Incorporated, has completed the bio-distribution studies on its DFH-12 product candidate for the PulmoBind technology of molecular imaging of the lung's vascular system. The completion of this study is a milestone for the company, proving the success of their molecule, code named DFH-12, and its application in other imaging technologies. DFH-12 works, via injection, because the molecule is designed to bond only to the inner walls of the vascular system of the lungs. The DFH-12 molecule is tagged with a radionuclide, so the integrity of the lung's vascular system can…